Gapping up
In reaction to earnings/guidance:
- CSOD +14.9%, KRNT +12.4%, ANDE +8.8%, QS +7.6%, WIX +4.7%, SAH +4.2%, DIOD +3.2%, SEDG +3%, CLR +2.9%, EQT +2.8%, RIO +2.6%, NOMD +2.6%, IRWD +2.5%, A +2.4% (also authorizes $2 bln repurchase program), GRMN +2.3%, OC +2.1%, HEES +2%, BYD +1.9%, GNW +1.9%, CRK +1.4%, WIRE +1.4%, TSEM +1.4%, RPRX +1%, DVN +0.9%
Other news:
- AHAC +13.8% (Alpha Healthcare Acquisition Corp. and Humacyte announces business combination agreement)
- ALT +13.6% (announces FDA clearance of IND for Phase 1 trial of AdCOVID)
- VIR +11.6% (Vir Biotechnology and GSK expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses; GSK is increasing its equity investment by $120 mln and making an upfront payment of $225 mln)
- MESO +8.8% (announces publication of a paper on the first two children treated with Mesoblast's mesenchymal stromal cell (MSC) product candidate remestemcel-L for life-threatening multisystem inflammatory syndrome (MIS-C) associated with COVID-19)
- TPCO +6.4% (to be acquired by Alden Global Capital for $17.25 per share)
- DPW +5.8% (announces that it has amended the terms of its previously announced "at-the-market" equity offering program under which it may sell, from time to time, shares of its common stock for aggregate gross proceeds of up to $125,000,000, inclusive of the previously authorized $50,000,000)
- RDHL +5.2% (doses first patient in US Phase 2/3 COVID-19 outpatient study with RHB-107)
- CHRS +4.9% (FDA has accepted for review the 351(k) Biologics License Application for CHS-1420, a Humira biosimilar product candidate, and has set a Biosimilar User Fee Act action date for December 2021)
- OGE +2.1% (announces support of the merger agreement between Energy Transfer LP and Enable Midstream Partners LP)
- RBBN +1.1% (to sell Qualitech testing and standardization business)
- F +1.1% (says by mid-2026, 100% of its passenger vehicle range in Europe will be zero-emissions capable, all-electric or plug-in hybrid; moving to all-electric by 2030)
- ALSN +1% (announces partnership with American Rheinmetall Vehicles to provide propulsion system for the Lynx vehicle)
Analyst comments:
- ONCY +59.5% (initiated with a Buy at H.C. Wainwright $15)
- MESA +5.7% (upgraded to Buy from Underperform at BofA Securities)
- CREE +3.2% (upgraded to Buy from Neutral at Citigroup)
- CVI +2.7% (upgraded to Neutral from Underperform at Credit Suisse)
- A +2.4% (upgraded to Buy from Neutral at BofA Securities)
- OSK +2% (upgraded to Buy from Hold at Jefferies)
- PLTR +1.5% (upgraded to Buy from Neutral at Goldman)